Supernus Pharma
SUPN41.2100.05% ( -0.020 )
Supernus Pharma (SUPN)
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous s...
- Open
- 41.230
- High
- 42.000
- Low
- 40.860
- Prev. Close
- 41.230
- Volume
- 1.01M
- Turnover
- 41.53M
- Avg Price
- 41.266
- Bid/Ask Ratio
- --
- Amplitude
- 2.76%
- 52wk High
- 59.680
- Volume Ratio
- 2.09
- Turnover Ratio
- 1.94%
- 52wk Low
- 37.540
- Float Mkt Cap
- 2.13B
- Market CapUSD
- 2.40B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -1.89
- EPSDynamic
- -2.09
- EPSStatic
- --
- BVPS
- 17.74
- P/B
- 2.32
- Circulating Supply
- 51.74M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 58.13M
- Min lot size
- 1
- Currency
- USD
Supernus Pharma Analyst Rating
View moreForecast & Rating
Oct 21, 2026Price forecast
$60.5046.81%
Forecast & RatingBuy
4analysts
- Strong buy75.00%
- Buy0.00%
- Hold25.00%
- Sell0.00%
- Strong sell0.00%
News
- GlobeNewswire ·
Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)
- PUBT ·
Supernus Pharmaceuticals publishes update to financial calendar
- PUBT ·
Indivior Shareholders Approve Merger With Supernus
- PUBT ·
Supernus Pharmaceuticals Holds Special Stockholder Meeting
- Market Beat ·
Supernus Pharmaceuticals (NASDAQ:SUPN) Hits New 12-Month Low - Here's What Happened
- Simplywall ·
How Investors May Respond To Supernus Pharmaceuticals (SUPN) FDA Approval For ONAPGO
